4-HO-MPMI
Chemical compound
From Wikipedia, the free encyclopedia
4-HO-MPMI, also known as 4-hydroxy-N-methyl-(α,N-trimethylene)tryptamine or as lucigenol, is a psychedelic drug of the pyrrolidinylmethylindole and cyclized tryptamine families.[1]
| Clinical data | |
|---|---|
| Other names | 4-Hydroxy-N-methyl-(α,N-trimethylene)tryptamine; Lucigenol |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H17N2O |
| Molar mass | 229.303 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Interactions
Pharmacology
Pharmacodynamics

The affinity (Ki) of 4-HO-MPMI for the serotonin 5-HT2A receptor has been found to be 13 nM.[1] It produces psychedelic-appropriate responding in animal tests with similar potency as DOI.[1] The drug has two enantiomers, with only the (R)-enantiomer being active.[1]
Chemistry
Analogues
Analogues of 4-HO-MPMI include MPMI, 5-MeO-MPMI, 5F-MPMI, CP-135,807, 4-HO-McPeT, 4-HO-pyr-T, and SN-22, among others.
History
4-HO-MPMI was developed by the team led by David E. Nichols from Purdue University in the late 1990s.[1]
Society and culture
Legal status
Canada
4-HO-MPMI is not a controlled substance in Canada as of 2025.[2]